Option chain shows key data for HCW Biologics's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for HCW Biologics.

HCW Biologics (NASDAQ:HCWB) Stock, Option Chain

HCW Biologics

HCW Biologics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen the health span by disrupting the link between chronic, low-grade inflammation and age-related diseases. The company has developed TOBI discovery platform, or Tissue factor-based fusion discovery platform, for the design of category-defining immunotherapeutic drugs. It has selected two molecules as its product candidate; HCW9218 and HCW9302. HCW9218 is a bifunctional immunotherapeutic designed with the capabilities to neutralize transforming growth and stimulate immune cells. HCW9302 is designed to activate and expand regulatory T cells, which deactivate inflammasomes.

News

Penny Stocks

Small Cap

Intraday Update

Markets

Movers

Trading Ideas

AAOI

AFRM

APLM

ASST

AVXL

BDRX

BGLC

CAPT

CHWY

CLIR

HCWB

HUYA

INOD

IOBT

ITRN

MIRA

OXBR

PERF

PUYI

RDHL

RELI

RILY

SBET

SHOT

SNES

TCBP

Telecom Argentina Stet - France Telecom S.A.

THAR

VCXA

XENE

Shares of Anavex Life Sciences Corp. (NASDAQ: AVXL) moved lower during Monday’s session after the company reported fourth-quarter financial results.

Why Anavex Life Sciences Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Monday&#39;s Mid-Day Session

Long Ideas

Pre-Market Outlook

BARK

LFMD

NRDY

The Dow Jones closed higher by around 90 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company&#39;s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

Nerdy And 3 Other Stocks Under $4 Insiders Are Aggressively Buying

Insider Trades

AMPS

AUID

SBIG

The Dow Jones closed lower by over 100 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company&#39;s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

$3M Bet On This Technology Stock? Check Out These 4 Penny Stocks Insiders Are Aggressively Buying

HCW Biologics Inc

PLTR

Palantir Announces Transfer Of Stock Exchange Listing To Nasdaq On Nov. 26

iPower (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPW#NASDAQ">IPW</a>) reported quarterly losses of $(0.06) per share which missed the analyst consensus estimate of $0.02 by 400 percent. This is a 50 percent decrease over losses of $(0.04) per share from the same period last year. The company reported quarterly sales of $19.01 million which missed the analyst consensus estimate of $20.90 million by 9.05 percent. This is a 28.29 percent decrease over sales of $26.51 million the same period last year.

Earnings

Earnings Misses

iPower Q1 EPS $(0.06) Misses $0.02 Estimate, Sales $19.01M Miss $20.90M Estimate

Management

OMGA

Omega Therapeutics Appoints Kaan Certel, Ph.D As President As CEO

AMZN

BABA

MSFT

ORCL

Appaloosa LP 13F Shows Decreased Stake In Alibaba Group By 5% From 10,500,000 To 10,000,000 Shares; Decreased Stake In Amazon By 8% From 3,475,000 To 3,200,000 Shares;  Decreased Stake In Microsoft By 18% From 1,181,356 To 970,000 Shares; Decreased Stake In Meta Platforms By 33% From 935,000 To 625,000 Shares; Decreased Stake In Oracle By 21% From 2,000,000 To 1,573,394 Shares; Decreased Stake In Advanced Micro Devices By 17% From 1,370,000 To 1,135,000 Shares

AREN

Arena Group Holdings Q3 EPS From Continuing Operations $0.13 Up From $(0.37) YoY, Sales $33.56M Down From $36.99M YoY

WIIM

Arena Group shares are trading higher after it announced its first ever profitable quarter.

APLD

NVDA

13F Shows Nvidia Corp Added Stake In Applied Digital Corp With 7,716,050 Shares

IXHL

Incannex Healthcare Q1 EPS $(0.29) Down From $(0.08)

IZEA Worldwide (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IZEA#NASDAQ">IZEA</a>) reported quarterly losses of $(0.52) per share which missed the analyst consensus estimate of $(0.11) by 372.73 percent. The company reported quarterly sales of $8.832 million which missed the analyst consensus estimate of $10.750 million by 17.84 percent. This is a 11.87 percent increase over sales of $7.895 million the same period last year.

IZEA

IZEA Worldwide Q3 2024 GAAP EPS $(0.52) Misses $(0.11) Estimate, Sales $8.832M Miss $10.750M Estimate

BEKE

LYFT

Citigourp Global Markets 2% Protected Notes Linked To The Djia

Appaloosa LP 13F Shows Increased Stake In PDD Holdings By 173% From 1,940,000 To 5,301,132 Shares; Increased Stake In JD.com Inc By 69% From 4,310,600 To 7,300,000 Shares;  Increased Stake In Lyft By 98% From 7,961,257 To 15,750,000 Shares; Increased Stake In KE Holdings By 4% From 2,085,000 To 2,175,000 Shares

AST SpaceMobile (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASTS#NASDAQ">ASTS</a>) reported quarterly losses of $(1.10) per share which missed the analyst consensus estimate of $(0.20) by 450 percent. The company reported quarterly sales of $1.100 million which missed the analyst consensus estimate of $24.133 million by 95.44 percent.

ASTS

AST SpaceMobile Q3 2024 GAAP EPS $(1.10) Misses $(0.20) Estimate, Sales $1.100M Miss $24.133M Estimate

Surf Air Mobility Inc. Common Stock (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SRFM#NYSE">SRFM</a>) reported quarterly losses of $(0.94) per share which beat the analyst consensus estimate of $(2.10) by 55.24 percent. The company reported quarterly sales of $28.386 million which beat the analyst consensus estimate of $26.305 million by 7.91 percent. This is a 29.22 percent increase over sales of $21.967 million the same period last year.

Earnings Beats

SRFM

Surf Air Mobility Inc. Common Stock Q3 2024 GAAP EPS $(0.94) Beats $(2.10) Estimate, Sales $28.386M Beat $26.305M Estimate

Emeren Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SOL#NYSE">SOL</a>) lowers FY2024 sales outlook from $150.00 million-160.00 million to $97.00 million-102.00 million.

Guidance

Emeren Group Lowers FY2024 Sales Guidance from $150.00M-$160.00M to $97.00M-$102.00M  VS Est. $151.34M

Precision Optics Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POCI#NASDAQ">POCI</a>) reported quarterly losses of $(0.21) per share. This is a 162.5 percent decrease over losses of $(0.08) per share from the same period last year. The company reported $4.20 million in sales this quarter. This is a 2.88 percent decrease over sales of $4.32 million the same period last year.

POCI

Precision Optics Corp Q1 EPS $(0.21) Down From $(0.08) YoY, Sales $4.20M Down From $4.32M YoY

Contracts

AXON

Axon To Supply Royal Canadian Mounted Police (RCMP) With Body-Worn Cameras

Ryvyl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVYL#NASDAQ">RVYL</a>) reported quarterly losses of $(0.76) per share which missed the analyst consensus estimate of $(0.27) by 181.48 percent. This is a 26.67 percent decrease over losses of $(0.60) per share from the same period last year. The company reported quarterly sales of $12.61 million which missed the analyst consensus estimate of $13.92 million by 9.44 percent. This is a 27.88 percent decrease over sales of $17.48 million the same period last year.

RVYL

Ryvyl Q3 EPS $(0.76) Misses $(0.27) Estimate, Sales $12.61M Miss $13.92M Estimate

Hyliion Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HYLN#NYSE">HYLN</a>) reported quarterly losses of $(0.06) per share which beat the analyst consensus estimate of $(0.07) by 14.29 percent.

HYLN

Hyliion Holdings Q3 2024 GAAP EPS $(0.06) Beats $(0.07) Estimate

Super League Enterprise (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLE#NASDAQ">SLE</a>) reported quarterly losses of $(0.25) per share which beat the analyst consensus estimate of $(0.31) by 19.35 percent. This is a 78.45 percent increase over losses of $(1.16) per share from the same period last year. The company reported quarterly sales of $4.43 million which missed the analyst consensus estimate of $6.81 million by 34.91 percent. This is a 38.42 percent decrease over sales of $7.20 million the same period last year.

Super League Enterprise Q3 2024 Adj EPS $(0.25) Beats $(0.31) Estimate, Sales $4.43M Miss $6.81M Estimate

Biotech

Events

General

AMGN

Amgen To Present MITIGATE Phase 3 Study At ACR 2024 Nov. 14-19

Sidus Space (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIDU#NASDAQ">SIDU</a>) reported quarterly losses of $(0.93) per share. This is a 81.4 percent increase over losses of $(5.00) per share from the same period last year. The company reported $1.87 million in sales this quarter. This is a 89.65 percent increase over sales of $985.52 thousand the same period last year.

SIDU

Sidus Space Q3 EPS $(0.93) Up From $(5.00) YoY, Sales $1.87M Up From $985.52K YoY

HCW Biologics GAAP EPS of -$0.14, revenue of $1.1M

Michael Okunewitch, an analyst from Maxim Group, maintained the Buy rating on HCW Biologics (HCWB – Research Report). The associated price target r...

HCW Biologics: A Promising Buy Rating Based on Clinical Advancements and Strategic Growth Opportunities

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
HCW Biologics (NASDAQ:<a href="https://investorplace.com/stock-quotes/hcwb-stock-quote/">HCWB</a>) just reported results for the second quarter of 2024.<ul><li>HCW Biologics reported earnings per share of -40 cents.</li><li>The company reported revenue of $618,854.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/hcwb-stock-earnings-hcw-biologics-for-q2-of-2024/">HCWB Stock Earnings: HCW Biologics Reported Results for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

HCWB Stock Earnings: HCW Biologics Reported Results for Q2 2024

HCW Biologics reports Q2 results

Warning: HCWB is at high risk of performing badly

Press Releases

HCW Biologics Reports Fourth Quarter 2023 and Fiscal Year End Financial Results And Business Highlights

HCW Biologics Reports First Quarter 2024 Financial Results and Business Highlights

HCW Biologics Reports Second Quarter 2024 Financial Results and Business Highlights

Comments

HCW Biologics

HCW Biologics (HCWB) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga